Detailed Information

Cited 2 time in webofscience Cited 2 time in scopus
Metadata Downloads

Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study

Authors
Lee, Sun JaeYim, Hyung JoonHwang, Seong GyuSeo, Yeon SeokKim, Ji HoonYoon, Eileen L.Lee, Joong MinKim, Bo HyunPark, Sang JongPark, Young MinKim, Hong SooLee, Se HwanAhn, Sang HoonLee, Jeong IlLee, Jin WooKim, In HeeKim, Hyung SooHong, Sun Pyo
Issue Date
Feb-2013
Publisher
INFORMA HEALTHCARE
Keywords
adefovir; antiviral resistance; chronic hepatitis B; combination drug therapy; entecavir; lamivudine; multicenter study
Citation
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, v.48, no.2, pp.196 - 204
Indexed
SCIE
SCOPUS
Journal Title
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
Volume
48
Number
2
Start Page
196
End Page
204
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/10991
DOI
10.3109/00365521.2012.722671
ISSN
0036-5521
Abstract
Objectives. To compare the efficacy of rescue therapies in lamivudine (LAM)-resistant chronic hepatitis B (CHB) infections including: (1) adefovir dipivoxil (ADV) monotherapy, (2) ADV plus LAM combination therapy and (3) entecavir (ETV) 1.0 mg monotherapy. Materials and methods. The authors designed a multicenter-retrospective study. Eight institutions participated in the study from Korea. Results. A total of 343 LAM-resistant CHB patients were enrolled. The proportion of patients with undetectable serum hepatitis B virus (HBV) DNA levels at month 24 after the initiation of rescue therapy was higher in the ADV plus LAM combination therapy group (39/64, 60.9%) than in the ADV monotherapy (50/126, 39.7%) and ETV 1.0 mg monotherapy (19/48, 39.6%) groups (p = 0.014). Mean serum HBV DNA levels at 24 months were 2.07 +/- 1.21 log(10) IU/ml in the ADV plus LAM combination therapy group, 2.74 +/- 1.74 log(10) IU/ml in the ADV monotherapy group and 3.08 +/- 1.97 log(10) IU/ml in the ETV 1.0 mg monotherapy group (p = 0.014). In multivariate analysis, a finding of undetectable serum HBV DNA level at 6 months and ADV plus LAM combination therapy (vs. ADV) was an independent factor for predicting undetectable serum HBV DNA at month 24 (odds ratio, 1.003; 95% confidence interval, 1.000-1.006; p = 0.026). Conclusions. ADV plus LAM combination therapy is more effective in reducing viral load than switching to ADV or ETV 1.0 mg in patients with LAM-resistant CHB.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Ji Hoon photo

Kim, Ji Hoon
구로병원 (Department of Gastroenterology and Hepatology, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE